Tetravalent Multispecific Antibody Pairing Design for Higher Purity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing multispecific antibodies, such as tetravalent bispecific antibodies, suffer from the formation of undesired side products due to mispairing of heavy and light chains, which complicates the production process and reduces the purity and therapeutic applicability of these antibodies.
Innovation Solution
A tetravalent multispecific antibody design that incorporates domain crossovers and specific amino acid substitutions in the CH1 and CL domains, along with modifications in the CH3 domains to promote heterodimerization, thereby reducing the formation of mispaired byproducts and improving the yield and purity of the desired antibody molecule.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional methods for producing multispecific antibodies are used, then production process is simple, but formation of undesired side products due to mispairing occurs
Solution Approach 1:
The patent introduces specific amino acid substitutions at defined positions in the CH1 and CL domains (local regions) to create electrostatic attractions that guide correct heavy-light chain pairing. This localized modification approach maintains overall structural simplicity while precisely controlling pairing behavior at critical interfaces.
Solution Approach 2:
The patent modifies electrostatic parameters by introducing charged amino acid residues (e.g., lysine, arginine, glutamic acid, aspartic acid) at specific positions to create favorable electrostatic interactions. This changes the physical-chemical parameters of the interface to promote correct pairing and reduce mispairing of heavy and light chains.
2Manufacturing precision
If domain crossovers and amino acid substitutions are introduced to reduce mispairing, then purity of desired antibody improves, but device complexity increases
Solution Approach 1:
The complexity is confined to specific local regions (CH1 and CL domains with defined amino acid positions) rather than throughout the entire antibody structure. The rest of the antibody maintains conventional structure, thereby limiting complexity increase to only where necessary for controlling pairing.
Solution Approach 2:
The amino acid substitutions and domain crossover designs are pre-engineered into the antibody sequences before production. This preliminary design ensures correct pairing behavior is built-in from the start, avoiding the need for complex post-production purification or assembly steps.
3Productivity
If modifications are made to promote heterodimerization, then yield of desired antibody improves, but formation of mispaired byproducts may increase
Solution Approach 1:
The patent carefully balances electrostatic parameters by introducing complementary charged residues that create attraction forces strong enough to promote heterodimerization and improve yield, while the specific positioning and selection of charges ensure these forces are directional and specific to correct pairings, not generic aggregation.
Solution Approach 2:
The patent converts the potential harm of strong electrostatic interactions (which could cause non-specific aggregation) into a benefit by strategically positioning opposite charges only at interfaces between complementary heavy and light chains. This ensures the strong forces promote correct pairing rather than random aggregation.
Data Source
AI summary
The present invention relates to novel tetravalent multispecific antibodies, their manufacture and use.